Saturday 17 October 2026 Export ITRMF’s income statement to Excel — free account

Iterum Therapeutics PLC

In the quarter to September 2025, revenue grew 110.8%, EPS grew 33.3% and free cash flow fell 179.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.00 0.00 NaN

Follow ITRMF

Alert me

Market cap: $1.6M
P/E: 0.0×
Fwd P/E: −1.0×
Dividend yield: —
F-score: 2/9
Altman Z: −26.27
Beneish M: 22.81
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1.59

Revenue 0.92

Net Income (26.96)

Free Cash Flow (19.53)

Net Debt 10.21

Current Ratio 2.13

Debt/Equity (2.87)

P/E ratio 0.00

Fwd P/E (1.00)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 67.12%

Next Y EPS Growth 316.67%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 22.77%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 12.89%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	Q'25
Cash	61	24	24	11
Receivables	0	0	0	0
Inventory	—	—	—	1
Other	—	—	—	—
	62	26	25	14

	2022	2023	2024	Q'25
Payables	3	5	0	1
ST’ Debt	—	—	—	—
Other	2	1	15	0
	9	14	18	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	0	—	—
’19	0	—	—	—	0
’18	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(5)	(7)	—	—
’24	(13)	(7)	(3)	(4)	(27)
’23	(10)	(8)	(9)	(13)	(39)
’22	(3)	(6)	(5)	(4)	(18)
’21	(1)	(8)	(4)	(2)	(16)
’20	(27)	(14)	(4)	(9)	(55)
’19	(15)	(18)	(25)	(23)	(82)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(5)	(7)	—	—
’24	(13)	(7)	(3)	(4)	(27)
’23	(10)	(8)	(9)	(13)	(39)
’22	(3)	(6)	(5)	(4)	(19)
’21	(1)	(8)	(4)	(2)	(16)
’20	(27)	(14)	(4)	(9)	(55)
’19	(15)	(18)	(25)	(23)	(82)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.14)	(0.16)	(0.20)	—	—
’24	(0.46)	(0.30)	(0.30)	(0.25)	(1.26)
’23	(0.78)	(0.95)	(0.30)	(0.94)	(2.96)
’22	(0.30)	(0.60)	(2.38)	(0.41)	(3.63)
’21	(12.14)	0.60	0.30	(0.30)	(8.40)
’20	(16.19)	(11.99)	(9.00)	(4.20)	(32.53)
’19	(21.59)	(28.94)	(32.23)	(23.84)	(106.45)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	—	—	75.15	25.20	6.77	5.86	0.60	0.62	0.81	Analyst estimates 2025–2027 Powerpack
	High	—	—	—	195.00	139.51	90.30	44.93	7.05	2.50	3.02
People
People	Employees	—	—	38	48	44	7	13	14	14	9
	Revenue/emp, $m	—	—	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	1	1	0	—	—	—	—	—
	Gross margin, %	—	—	100.00	100.00	100.00	0.00	0.00	0.00	—	0.00
	EBT	—	(13)	(29)	(77)	(103)	(51)	(91)	(44)	(38)	(25)
	EBT margin, %	—	0.00	(5,701.18)	(8,812.89)	(277,529.73)	0.00	0.00	0.00	0.00	0.00
	Net income	—	(13)	(29)	(77)	(103)	(52)	(92)	(44)	(38)	(25)
	Depreciation	—	—	0	0	1	11	6	4	4	3
Per share, $
Per share, $	Revenue	—	0.00	44.17	1.49	0.04	0.00	0.00	0.00	0.00	0.00
	Earnings	—	(8,528.78)	(2,561.26)	(132.23)	(106.45)	(32.53)	(8.40)	(3.63)	(2.96)	(1.26)
	Cash flow	—	(7,061.25)	(2,661.22)	(130.26)	(84.60)	(34.05)	(1.45)	(1.51)	(3.03)	(1.36)
	Capex	—	0.00	(70.61)	(0.15)	(0.02)	(0.01)	(0.01)	(0.01)	0.00	0.00
	Free cash flow	—	(7,061.25)	(2,731.83)	(130.42)	(84.62)	(34.05)	(1.46)	(1.51)	(3.04)	(1.36)
	Book value	—	14,186.25	3,434.26	122.94	(27.09)	(31.57)	4.61	2.29	(0.49)	(0.21)
	Shares, m	—	0	0	1	1	2	11	12	13	20
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	—	—	—	—	—
	P/S	—	—	0.00	50.38	91.42	—	—	—	—	—
	P/B	—	—	0.11	0.61	0.00	—	—	—	—	—
	EV/Sales	—	—	0.00	(30.73)	103.44	—	—	—	—	—
	EV/FCF	—	—	0.52	0.35	(0.90)	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(11)	(31)	(76)	(82)	(55)	(16)	(18)	(39)	(27)
	Capex	—	—	(1)	0	0	0	0	0	0	0
	Free cash flow	—	(11)	(31)	(76)	(82)	(55)	(16)	(19)	(39)	(27)
Balance, $m
Balance, $m	Working capital	—	22	37	81	(25)	(20)	70	53	12	7
	Total debt	—	—	—	14	13	29	9	10	11	20
	Net debt	—	(25)	(39)	(70)	9	14	(73)	(51)	(12)	(4)
	Shareholders’ equity	—	23	39	72	(26)	(51)	50	28	(6)	(4)
Returns, %
Returns, %	ROA	—	(36.55)	(79.83)	(106.56)	(166.85)	(177.67)	(147.33)	(56.12)	(82.44)	(69.93)
	ROIC	—	0.00	(6,622.08)	(4,201.00)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	(43.29)	(94.61)	(138.69)	(454.48)	135.44	56,347.08	(113.59)	(355.35)	472.61

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2019 · latest quarter Sep 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SILO Silo Pharma, Inc.	$1.9M	— (loss-making)	18.4×	0.00%	n/m	+39.17% (above 0%: growing)	(15.00%)	0.00%	Compare
GNPX GENPREX	$1.9M	0.0×	—	—	n/m	−32.98% (below 0%: shrinking)	0.00%	0.00%	Compare
TRVN Trevena, Inc.	$1.8M	— (loss-making)	— (loss-making)	+57.22% (above 0%: growing)	n/m	+49.55% (above 0%: growing)	59.72%	(1,970.67%)	Compare
NEXI NexImmune, Inc.	$1.6M	— (loss-making)	—	—	n/m	+66.38% (above 0%: growing)	0.00%	0.00%	Compare
ITRMF Iterum Therapeutics PLC	$1.6M	— (loss-making)	— (loss-making)	+110.81% (above 0%: growing)	n/m	−179.15% (below 0%: shrinking)	94.87%	(1,982.31%)
CARM Carisma Therapeutics Inc.	$1.5M	— (loss-making)	— (loss-making)	+392.01% (above 0%: growing)	n/m	+114.65% (above 0%: growing)	100.00%	96.83%	Compare
ARTL Artelo Biosciences, Inc.	$1.5M	— (loss-making)	—	—	n/m	−879.18% (below 0%: shrinking)	0.00%	0.00%	Compare
ABPO Abpro Holdings Inc.	$1.4M	0.2×	—	—	n/m	−0.48% (below 0%: shrinking)	100.00%	0.00%	Compare
MLEC Moolec Science SA	$1.4M	— (loss-making)	— (loss-making)	+948.39% (above 0%: growing)	n/m	+4.48% (above 0%: growing)	(25.52%)	(77.92%)	Compare
Median of peers	$1.6M	—	—	+224.62%	—	+21.83%	0.00%	0.00%